Compare United Microelectronics Corp (UMC) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Microelectronics Corp vs 22nd Century Group Inc — how do they compare? United Microelectronics Corp trades at $22.89 (market cap $58.02B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: United Microelectronics Corp is far larger — about 93329.3× 22nd Century Group Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold United Microelectronics Corp for 42 Days and 22nd Century Group Inc for 32 Days on average.
| UMC | XXII | |
|---|---|---|
Market Cap | $58.02B | $621.67K |
Volume | 11,897,809 | 45,625 |
Sector | Technology | Consumer Staples |
52-Week High | $28.02 | $483.00 |
52-Week Low | $7.02 | $0.80 |
Typical Hold Time | 42 Days | 32 Days |
Enterprise Value | $55.10B | -$3.69M |
Dividend Yield | 1.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
United Microelectronics (UMC) trades at $22.96, down 1.5% on the day, with strong fundamental performance including three consecutive quarterly earnings beats. The stock shows a bullish technical signal despite bearish moving averages, with support at $22 and resistance at $23-24. Revenue growth is projected to accelerate from $237.6B in 2025 to $250.7B in 2026, while net income margins are expected to improve significantly from 16.99% to 32.75%.
UMC presents a compelling investment case with robust earnings momentum and improving profitability, though mixed analyst sentiment and competitive pressures in the semiconductor foundry space warrant caution. The stock's current valuation (P/E 22.03, P/S 7.15) appears reasonable given projected earnings growth, but investors should monitor AI spending trends and capacity utilization rates that drive semiconductor demand cycles.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
